Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. - Wikidata - wikimedia - TriplyDB

Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.

Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.

http://www.wikidata.org/entity/Q54518446

about

Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions The epigenetic landscape of acute myeloid leukemia Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases Myeloid malignancies: mutations, models and management Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations Myeloid neoplasias: what molecular analyses are telling us Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes.Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms.Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms.An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts A TET2 rs3733609 C/T genotype is associated with predisposition to the myeloproliferative neoplasms harboring JAK2(V617F) and confers a proliferative potential on erythroid lineages.ASXL1 plays an important role in erythropoiesis.Xist RNA is a potent suppressor of hematologic cancer in mice.Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms.Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.Myelofibrosis: an update on current pharmacotherapy and future directions.Emerging drugs for polycythemia vera.Genetic events other than BCR-ABL1.Molecular genetics of myelofibrosis and its associated disease phenotypes.Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.Epigenetic modifiers in normal and malignant hematopoiesis.ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival.ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesis.Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome.

P2860

Q21261481-63FB24CB-2FE9-492C-BBCF-6DBD1454B161 Q21284742-25A430CE-4C79-402B-9A89-493E7A84E7B3 Q26738514-96FB806A-4A2E-4476-8E85-F2B5913BB78F Q26774212-F2BD1052-8E8A-4F18-9F85-8380626793E0 Q26851894-745FFBCA-2793-44E6-A262-C5FED188F18F Q26852269-4897C008-B2BF-4BA8-A21C-BD64E2A844EC Q27000577-BEDE687E-867B-4D2D-845F-42438EB8B517 Q27853094-DC1F7AA9-584F-4FCB-9AFC-923112E60A21 Q33354547-B753C7CB-1246-4BDE-A475-62C42495428D Q33558154-AC653774-9069-4E74-8563-417AF2987C5C Q33558793-56BDA977-9AEA-4C28-A833-8B2A1407D1DF Q33629603-1991F454-9D18-4117-AA8A-2F98277AB65C Q33667448-EE5DFF02-3129-4857-80FF-66231EAA7F63 Q34302770-61352D8F-FE47-4A96-98A1-16631B6BEF35 Q34467863-B4454D75-E252-44B5-BFF7-76E702CC8D19 Q35777306-400B38F3-5836-4A31-A65E-D125BB8C80FB Q36364763-6C551222-8722-4DAA-9B08-035407D26573 Q36579162-02E94C29-EAF3-48DA-8A92-56B910416F07 Q36708989-28F87146-56B0-48F5-944B-BDA44BC8854D Q36782943-D04FC129-9F48-44FD-AF56-9B0A67BF0EE4 Q36936451-390B7283-C46A-4566-97A3-24EDAD1C5BAD Q36962675-6AD990A1-E56E-4DCD-BADE-FC8E7BCDA3E9 Q37049843-3157CF16-A523-4910-AEAC-31A1959675AF Q37419610-06A1B013-2426-4BE3-A213-09751B84735F Q37512080-8A5B3056-93C8-4079-85EF-7FBAE8FF9EE4 Q37555785-472E7494-63E3-4924-BEDB-F6D78E7629F9 Q37742267-8CFBB1ED-9DAE-423C-AFFA-3EC0D86E75E7 Q37995804-8C07CAE3-0CA7-4A83-8786-9FEC5FAD3B3C Q38046319-82A56031-0A5F-407B-AA5B-6A09AFE9ED38 Q38076672-7C57B9AE-1680-452E-BA31-F59EC40FD17B Q38091447-69A441E2-5DC2-4C4A-8686-64800C5A9AC5 Q38130749-93551292-B52D-43F9-B5AA-6BB7CC15D7F6 Q38177162-9A69913F-82DF-47A3-898C-A50CB1C1A3AE Q38208010-3C2EC00E-73E2-4E63-ABC1-1410671D3244 Q38225521-BD4EA90E-006E-4CF0-A25A-147691DAF192 Q38459577-FDD3C4D9-841D-42BB-B7EF-B44D349A288C Q38459868-5C2ED0A9-04D5-408E-8A30-B843F4BE15BC Q38777486-6D718B9B-98FD-4818-AB72-5246F556DFBD Q39003064-2970C264-EAE5-4A17-AD70-E88EFC7BB7A7 Q39083031-62FD02BB-9633-45FD-9759-673FA92FDEA0

P2860

Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.

http://www.wikidata.org/entity/Q54518446

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Mutation analysis of ASXL1, CB ...... myeloproliferative neoplasms.

@en

Mutation analysis of ASXL1, CB ...... myeloproliferative neoplasms.

@nl

type

label

Mutation analysis of ASXL1, CB ...... myeloproliferative neoplasms.

@en

Mutation analysis of ASXL1, CB ...... myeloproliferative neoplasms.

@nl

prefLabel

Mutation analysis of ASXL1, CB ...... myeloproliferative neoplasms.

@en

Mutation analysis of ASXL1, CB ...... myeloproliferative neoplasms.

@nl

P1433

Q54518446-04946215-8149-419B-A821-2D24FE31326C

P1476

Q54518446-0517F5C5-325D-4E18-A466-8D26E2650792

P2093

Q54518446-2FDECE8F-0684-47EE-8746-7F6BED1B764F

Q54518446-38E8623A-11F4-4F42-98FC-3C105097815C

Q54518446-474EECD4-20C9-42D4-828D-6FB54BC6500E

Q54518446-4988D058-AB78-4EED-8D91-8622FF7E4A5E

Q54518446-54821348-6742-40C5-99AE-7C76F6347BAB

Q54518446-89EB299F-3332-42F0-B943-70F709FB6BC9

Q54518446-902D7E30-EA29-49EB-8AE9-34CA67A483F9

Q54518446-92F71FB4-D503-4887-85CD-0B59FF5FD651

Q54518446-9E42662C-C066-4A02-863F-3D151131AB3E

Q54518446-A6055B1C-9370-44F7-842E-75742FC398A5

P2860

Q54518446-051013A2-64DE-4738-9BE7-C899FEA29AC6

Q54518446-09A502C6-15F8-4506-B103-A685D849CC72

Q54518446-0B62900D-247B-475A-A6CA-6D50EB3A9AE5

Q54518446-0E13097D-87D6-43A0-A369-D8DB8D7683CD

Q54518446-0F88F8E6-7AB3-4516-98B6-CAA3A634D8C9

Q54518446-1A1FA8B9-5DDA-4EDA-B0FB-380D2DB87CB5

Q54518446-24C3C140-6CDD-446B-9B39-0FB28FD5AEE0

Q54518446-2CBA2AD1-13C5-41E8-89E1-C374C8018852

Q54518446-3456437F-90EF-4930-B5CB-270DCDFF7544

Q54518446-36EDB1E6-1EF5-4245-9916-4798884D6DAF

P304

Q54518446-08F0A8F4-AFBA-4AB9-93D0-85CD1CFECBD3

P31

Q54518446-9AE1236E-628F-4577-9F10-7A2A947695DE

P356

Q54518446-B63D20C3-6E09-4A29-8A34-D9A4267CC597

P433

Q54518446-C393E8C0-133E-4EDC-93E6-C8C9AFD1CD7B

P478

Q54518446-16C6D29E-2CE2-47E9-BBCC-13EC1FF2D05F

P577

Q54518446-3031DB61-975B-4D3A-8AD7-9F2FE4326DB2

P5875

Q54518446-252DED79-7D97-4F19-B862-63DDA84B46B9

P698

Q54518446-55283ABE-3CCA-417B-A930-AF8AB1897871

P356

P1433

Genes, Chromosomes and Cancer

P1476

Mutation analysis of ASXL1, CB ...... myeloproliferative neoplasms.

@en

P2093

Anne Murati

http://www.w3.org/2001/XMLSchema#string

Borhane Slama

http://www.w3.org/2001/XMLSchema#string

Christine Arnoulet

http://www.w3.org/2001/XMLSchema#string

Daniel Birnbaum

http://www.w3.org/2001/XMLSchema#string

Denis Verrot

http://www.w3.org/2001/XMLSchema#string

Emilie Coppin

http://www.w3.org/2001/XMLSchema#string

François Bertucci

http://www.w3.org/2001/XMLSchema#string

Jérôme Rey

http://www.w3.org/2001/XMLSchema#string

Mandy Brecqueville

http://www.w3.org/2001/XMLSchema#string

Marie-Joelle Mozziconacci

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB

Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

DNMT3A Mutations in Acute Myeloid Leukemia

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

P304

743-755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/GCC.21960

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223970606

http://www.w3.org/2001/XMLSchema#string

P698

22489043

http://www.w3.org/2001/XMLSchema#string